Karin Conde-Knape is Senior Vice President for Global Drug Discovery within Novo Nordisk, where she is responsible for driving the early pipeline and innovation within the areas of Diabetes, Obesity, Cardiovascular, Renal, Rare endocrine and metabolic diseases. She has more than 20 years of executive experience within the pharmaceutical industry within different areas of responsibility, including project leadership, line management, strategic planning and execution as well as business development. Karin spent 11 years at Hoffman-La Roche in the Cardiovascular and Metabolism Discovery and early development areas, responsible for pharmacology teams as well as discovery and biomarker teams. Before joining Novo Nordisk, she worked four years at Johnson and Johnson, responsible for external innovation in Europe and Asia Pacific in Cardiovascular and Metabolism. During these years she led cross functional teams in the evaluation for external opportunities and creating the business cases to support deal making for different external opportunities.